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Background: The presence of hypovitaminosis D in patients with autoimmune bullous skin diseases, such as
pemphigus vulgaris (PV) and bullous pemphigoid (BP), is debated. In a previous study we found an increased
prevalence of vertebral fractures (VFx) and hypovitaminosis D in PV and BP patients. The present study extends the
sample size of the previous one, for investigating the 25-hydroxyvitamin D (25OHVitD) levels in relation with the
skeletal health and disease intensity in these patients.
Methods: The previous study was performed in 13 PV and 15 BP patients and 28 controls. Data from 39 additional
patients (22 PV and 17 BP) were now added. Eventually, we studied 67 patients (35 PV, 32 BP, 51 females), aged
64.7 ± 16.9 years and 67 age- gender- and body mass index-matched controls. In all subjects, serum 25OHVitD,
calcium and alkaline phosphatase (ALP) levels were measured, bone mineral density (BMD) was evaluated by
Dual-energy X-ray. Absorptiometry at lumbar spine (LS) and femoral neck (FN) and the presence of VFx were
ascertained by visual assessment from spinal radiographs. In patients, the disease intensity was evaluated by the
autoimmune bullous skin disorder intensity score (ABSIS).
Results: As compared with controls, both PV and BP patients showed lower 25OHVitD (22.2 ± 11.1 vs 13.9 ± 8.3 ng/mL,
p < 0.001 and 22.4 ± 14.9 vs 9.5 ± 7.7 ng/mL, p < 0.0001, respectively) and higher prevalence of severe hypovitaminosis
D (22.9 vs 48.6%, p < 0.02 and 31.1 vs 75.0%, p < 0.0001, respectively) and VFx (28.6 vs 57.1%, p = 0.03 and 34.4 vs 62.5%,
P = 0.02, respectively). In both PV and BP patients, LS and FN BMD did not differ from controls. In the whole patients’
group, ABSIS score was inversely associated with 25OHVitD levels (R = −0.36, p < 0.005), regardless of age (β = −3.2,
P = 0.009).
Conclusions: PV and BP patients have an increased prevalence of hypovitaminosis D and VFx. The extended study
shows, for the first time, that the 25OHVitD levels are inversely associated with disease intensity and that VFx occur in
spite of a not reduced BMD.
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Recently, vitamin D has been suggested to influence the
immune system, triggering or exacerbating autoimmun-
ity [1], and hypovitaminosis D has been shown to be as-
sociated with the prevalence and severity of different
autoimmune disorders [2-4].
Pemphigus vulgaris (PV) and bullous pemphigoid (BP)
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unless otherwise stated.year, respectively) and potentially life-threatening auto-
immune bullous skin disorders [5-9]. PV is caused by auto-
antibodies to the desmosomal desmogleins (Dsg3-specific
autoantibodies and Dsg1-specific autoantibodies), while
two hemidesmosomal antigens, BP180 and BP230, are in-
volved in BP [10]. To date, immunosuppressive agents,
particularly corticosteroids, represent the treatment of
choice for both diseases [11,12]. However, regardless of the
use of corticosteroid, autoimmune conditions may lead to
a skeletal damage characterized by decreased bone mineral
density (BMD) and increased risk of fractures [13]. The
skeletal involvement in autoimmune diseases is thought toal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ably co-stimulatory receptors and cytokines [13], which
may be regulated by the 25-hydroxyvitamin D (25OHVitD)
levels [14].
Recently, the issue of hypovitaminosis D in autoimmune
bullous skin disorders has become a matter of debate,
since some studies suggested an increased prevalence of
hypovitaminosis D in PV and BP patients [15,16], while
others failed to find such associations [17,18]. These dis-
cordances may be related to the small sample size of the
available studies and to the frequency of hypovitaminosis
D even in the healthy populations [19]. However, this topic
is of pathophysiologic importance since the condition of
hypovitaminosis D has been suggested to play a role in the
pathogenesis of a number of immune-mediated inflamma-
tory disorders, including autoimmune bullous diseases
[16,17,20]. On the other hand, from a clinical point of
view, the presence of a bone damaging cytokine mili-
eau together with a condition of hypovitaminosis D
may render the PV and BP patients at risk of fragility
fractures [21].
Therefore, the aim of the present study was to evaluate
in a large sample of PV and BP patients, the skeletal me-
tabolism, 25OHVitD levels, bone mineral density (BMD)
and the prevalence and severity of vertebral fractures
(VFx) in relation to the disease intensity.Methods
Patients
The present investigation is the extension of a case–con-
trol study, performed in our Hospital between June 2009
and June 2011, in which 13 PV and 15 BP Caucasian pa-
tients and 28 matched controls were included [15]. Be-
tween July 2012 and June 2014, 49 additional Caucasian
patients referred to our Dermatology Unit for PV (n = 28)
or BP (n = 21) were consecutively evaluated for the study
inclusion. Among these, 10 patients (6 with PV and 4 with
BP) were excluded for the presence of already known con-
comitant active diseases (endocrine, neoplastic or inflam-
matory) and/or intake of drugs (i.e. bone anabolic or
antiresorptive drugs) potentially affecting bone metabol-
ism and mass. Eventually, 39 patients (22 with PV and 17
with BP) were enrolled in the extension study.
As a prerequisite for the enrolment in the study, the
detection of autoantibodies in the skin and in serum had
to be positive in all patients [22]. In all PV patients, the
diagnosis of active disease was based on typical blisters
and/or erosions of the skin and mucous membranes, to-
gether with the presence of intercellular IgG deposition
with or without C3 on direct immunofluorescence (DIF)
and detection of circulating Dsg3-specific autoantibodies
(with or without Dsg1-specific autoantibodies) by enzyme-
linked immunosorbent assay (ELISA) [11].In all BP patients, the diagnosis of active disease was
established on the basis of the presence of blisters and/
or erosions of the skin and/or erythematous-oedematous
skin lesions as well as the typical immunopathological
criteria [23], such as linear deposition of IgG and/or C3
at the basement membrane zone (BMZ) on DIF and cir-
culating levels of anti-BP180 and/or anti-BP230 auto-
antibodies on ELISA. At the enrolment no BP patients
had mucosal involvement.
At the enrolment all PV and BP patients showed active
disease and were “baseline”. Baseline is defined as the day
that therapy is started by a physician, according to recently
published recommendations by an international panel of
experts [24]. In all PV and BP patients, the disease intensity
was assessed by the autoimmune bullous skin disorder in-
tensity score (ABSIS) which is based on two clinical criteria,
such as the extent of the affected area and the quality of the
skin and mucosal lesions [25]. We decided to evaluate only
cutaneous ABSIS score for a reason of homogeneity, since
BP patients presented only with cutaneous lesions.
On the basis of the same exclusion criteria used for
PV and BP patients, in the extension study, we enrolled
as control group 39 Caucasian subjects selected from
the cohort of inpatients affected with an incidentally dis-
covered adrenal mass (adrenal incidentaloma, AI) and
admitted in the Endocrinology Unit of our hospital for
the hormonal evaluations. The AI diagnosis was based
on the finding of unilateral adrenal mass by non-invasive
imaging methods of the abdomen, performed for unre-
lated diseases. At computed tomography, all adrenal
masses showed typical features of adrenocortical aden-
omas and all control subjects did not show clinical and/or
biochemical signs of subclinical hypercortisolism, pheo-
chromocytoma and aldosteronoma. Among the AI sub-
jects, 35 and 32 were selected and matched for gender, age
and body mass index (BMI) with PV and BP patients, re-
spectively, and were evaluated in the same month of the
year of his/her respective PV or BP patient.
We decided to enroll patients with adrenocortical aden-
omas in order to avoid the possible bias related to a differ-
ent setting (i.e. inpatient vs outpatient). Indeed, as for PV
and BP patients, the subjects bearing an adrenal mass
were admitted as inpatients for the complex endocrine
workup. Eventually, only patients without adrenal hyper-
function were enrolled in the study and served as controls.
In control subjects, the skin type was comparable to
their respective PV and BP patients as evaluated by the
Fitzpatrick Scale (PV Group: 11 patients with skin type II,
18 with skin type III and 6 with skin type IV; PV Controls:
9 subjects with skin type II, 21 with skin type III and 5
with skin type IV; BP Group: 16 patients with skin type II,
13 with skin type III and 3 with skin type IV; BP Controls:
18 subjects with skin type II, 11 with skin type III and 3
with skin type IV).
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Board (Ethical Committee Fondazione IRCCS Cà Granda
Milan, Italy) and all the subjects gave their written in-
formed consent before participating in the study.
We present data regarding patients enrolled in the ex-
tension study and we provide a pooled analysis of patients
and controls enrolled in the previous and extension study.Methods
At the study entry, in all subjects serum 25-hydroxyvitamin
D (25OHVitD), serum calcium corrected for serum albu-
min (reference interval 8.4-10.2 mg/dL), and total alkaline
phosphatase (ALP) (reference interval 35–104 UI/L) were
measured by standard colorimetric techniques. Serum
25OHVitD levels were measured by radioimmunoassay
(RIA; DiaSorin) (reference interval: 30–120 ng/ml) [14]. Se-
vere hypovitaminosis D was defined as the presence of
25OHD levels below 12 ng/mL (reference interval: 30–
120 ng/ml). During the sample collection visit, the daily
sun exposure over the previous week was assessed via a
dedicated questionnaire [15]. Bone mineral density (BMD)
was measured by Dual-energy X-ray Absorptiometry
(DXA) (Hologic Discovery, Watham MA, USA) at lumbar
spine (LS) and femoral neck (FN) and expressed as stand-
ard deviation (SD) units in relation to the reference healthy
population of same age (Z-score) and of the young adults
(T-score). Diagnosis of osteoporosis was made in the pres-
ence of T-score at any site < −2.5 and/or presence of clinical
or asymptomatic low energy fractures. Vertebral fractures
were diagnosed on visual inspection of conventional spinal
radiographs in lateral and antero-posterior projection using
the semi-quantitative visual assessment, as previously
reported [15].Statistical analysis
Statistical analysis was performed by SPSS version 21.0
statistical package (SPSS Inc, Chicago, IL). The results are
expressed as mean ± SD. Categorical variables were com-
pared by χ2 test or Fischer exact test, as appropriate. For
each variable, the normality of distribution was tested with
the W statistic of Shapiro-Wilk. Normally distributed data
were compared, after testing homogeneity of variance, by
Student’s t test. The Mann–Whitney test was used when
the normality test failed. The associations between vari-
ables were tested by Pearson’s product moment correl-
ation or Spearman’s rank order correlation, as appropriate.
The multivariate regression analysis was used to assess the
independent association between ABSIS score, 25OHVitD
levels and age, that were shown to be associated among
themselves by Pearson’s product moment correlation or
Spearman’s rank order correlation. P-values of less than
0.05 were considered significant.Results
The comparison of the clinical characteristics between the
group of patients and their matched controls enrolled in
the extension study is summarized in Additional file 1:
Table S1. Patients showed lower 25OHVitD and ALP
levels and higher prevalence of severe hypovitaminosis D
and VFx than controls, while BMD at any site was com-
parable. Calcium levels tended to be lower in patients than
in controls, while the Sun Exposure Score and the
prevalence of current smokers and of patients with his-
tory of clinical fractures were comparable between pa-
tients and controls. In the control group mean vitamin
D levels were in the range of insufficiency (i.e. between
20 and 30 ng/mL), while calcium and ALP levels were
within the normal range.
The comparison of the clinical characteristics between
the whole group of patients and their matched controls
included in both previous and extension study is sum-
marized in Additional file 1: Table S2. Beside age, gender
and BMI, the Sun Exposure Score and the prevalence of
current smokers and of patients with history of clinical
fractures were comparable between patients and con-
trols. Patients showed lower 25OHVitD, calcium and
ALP levels and higher prevalence of severe hypovitami-
nosis D and VFx than controls, while BMD at any site
was comparable.
The clinical characteristics between PV and BP pa-
tients and their matched controls are reported in Table 1.
In PV and BP patients age, gender, BMI, Sun Exposure
Score and the prevalence of subjects with history of clin-
ical fractures and of current smokers were comparable
as compared to the matched controls.
As compared to controls, PV patients showed lower
25OHVitD and alkaline phosphatase levels and higher
prevalence of severe hypovitaminosis D and VFx, while
calcium levels and BMD at any site were comparable. No
correlation was found between Dsg3-specific autoanti-
bodies or Dsg1-specific autoantibodies and 25OHVitD
levels.
Patients with BP showed lower calcium and 25OHVitD
levels and higher prevalence of severe hypovitaminosis D
and VFx than controls, while BMD at any site was com-
parable. In BP patients, 25OHVitD levels were inversely
correlated with serum BP180 antibody levels (R = −0.40,
p = 0.04).
In the whole group of patients, the 25OHVitD levels
were inversely associated with ABSIS score (R = −0.36,
p < 0.005, Figure 1) and with age (R = −0.34, p = 0.05).
Separately analyzing PV and BP patients, this association
remained significant only in the latter group (R = −0.15,
p = 0.4 and R = −0.39, p = 0.03, respectively).
The multivariate regression analysis showed that
the ABSIS score was associated with 25OHVitD levels
(β = −3.2, P = 0.009), regardless of age (β = 0.11, P =
Table 1 Characteristics of the whole sample of patients with Pemphigus Vulgaris (PV) and Bullous Pemphigoid (BP)
and the respective controls
PV controls
(n = 35)*
PV patients
(n = 35)*
P value BP controls
(n = 32)*
BP patients
(n = 32)*
P value
Age (years) 53.7 ± 14.9 (27 – 79) 55.5 ± 14.6 (27 – 79) 0.608 76.7 ± 9.2 (59 – 90) 79.0 ± 9.9 (48 – 90) 0.324
Gender (females) 19 (54.3) 19 (54.3) 1.000 17 (53.1) 17 (53.1) 1.000
BMI (kg/m2) 26.0 ± 4.3 (19.9 –37.0) 25.1 ± 5.0 (18.4 – 39.0) 0.661 27.9 ± 4.6 (20.3 – 36.0) 26.7 ± 4.0 (17.6 – 36.7) 0.284
N. of current smokers (%) 10 (28.6) 7 (20.0) 0.403 5 (15.6) 3 (9.4) 0.708
N. of subjects with history
of clinical fractures (%)
4 (11.4) 1 (2.9) 0.356 5 (15.6) 3 (9.4) 0.708
Sun exposure score 13.7 ± 6.9 (4 – 28) 14.1 ± 5.8 (7 – 32) 0.791 9.9 ± 7.4 (2 – 26) 9.9 ± 7.3 (2 – 33) 0.851
Calcium (mg/dL) 9.2 ± 0.3 (8.7 – 9.7) 9.1 ± 0.4 (8.2 – 10.0) 0.513 9.3 ± 0.3 (8.6 – 10.0) 9.0 ± 0.3 (8.3 – 9.8) 0.001
25(OH) Vitamin D (ng/mL) 22.2 ± 11.1 (6.4 – 53.0) 13.9 ± 8.3 (4.0 – 34.8) 0.001 22.4 ± 14.9 (4.0 – 79.0) 9.5 ± 7.7 (4.0 – 31.8) 0.000
N. of subjects with severe
hypovitaminosis D (%)
8 (22.9) 17 (48.6) 0.025 10 (31.3) 24 (75.0) 0.000
Alkaline phosphatase (U/L) 72.7 ± 19.1 (38 – 115) 60.4 ± 19.5 (35 – 128) 0.013 71.0 ± 17.2 (39 – 105) 64.9 ± 18.2 (34 – 105) 0.173
LS BMD (Z-score) 0.21 ± 1.42 (−2.0 – 3.7) 0.35 ± 1.67 (−3.2 – 3.3) 0.717 −0.03 ± 1.47 (−2.6 – 3.8) 0.06 ± 1.65 (−2.9 – 3.1) 0.831
FN BMD (Z-score) −0.14 ± 1.04 (−1.6 – 2.7) 0.00 ± 1.31 (−2.9 – 3.0) 0.614 −0.26 ± 1.0 (−2.0 – 2.2) −0.20 ± 0.83 (−1.7 – 1.8) 0.766
N. of subjects with T-score
< −2.5 at any site (%)
4 (11.4) 8 (22.9) 0.342 9 (28.1) 12 (37.5) 0.424
N. of subjects with
vertebral fractures (%)
10 (28.6) 20 (57.1) 0.029 11 (34.4) 20 (62.5) 0.024
Data are mean ± SD with range or percentage in parentheses for continuous or categorical variable, respectively.
*The table includes data from an already published study [reference #15] in which 28 patients (13 with PV and 15 with BP) and 28 matched controls were
included, together with data from the extension arm of the study on 39 patients (22 with PV and 17 with BP) and 39 matched controls.
Severe hypovitaminosis D was defined in the presence of 25OHVitD levels <12 ng/mL (reference interval: 30–120 ng/ml).
Sun Exposure score: participants’ recollection of daily sun exposure over the previous week was assessed via a questionnaire administered (see reference #30)
Z-score, T-score: difference in standard deviation units in relation to the reference healthy population of same age (Z-score) and of the young adults (T-score).
Alkaline Phosphatase reference interval: 35–104 U/L. BMI: body mass index; BMD: bone mineral density; LS: lumbar spine; FT: total femur; FN: femoral neck.
Marzano et al. Orphanet Journal of Rare Diseases  (2015) 10:8 Page 4 of 70.337). Interestingly, all patients with 25OHVitD levels
above 15 ng/ml showed ABSIS score <20. On the other
hand, in the presence of 25OHVitD levels below 15 ng/ml
22 and 28 patients showed ABSIS score <20 and ≥20,
respectively.
Discussion
This study was aimed to investigate the issue of hypovi-
taminosis D and skeletal health in patients with auto-
immune bullous skin diseases. We found that PV and
BP patients with active disease had lower 25OHVitD
levels and higher prevalence of severe hypovitaminosis D
as compared with matched control subjects. Moreover,
PV and BP patients showed increased prevalence of verte-
bral fractures in spite of not reduced BMD. Finally, the dis-
ease severity was found to be associated with 25OHVitD
levels regardless of age.
Previous studies gave discordant results regarding the
prevalence of hypovitaminosis D in patients with auto-
immune bullous skin diseases. Indeed, our previous find-
ing of low 25OHVitD levels in PV and BP patients [15]
was confirmed by subsequent data [16] and by the re-
sults of the present extension study, but not by two
other studies [17,18]. This discordances may be due tothe small sample size of the previous studies and to the
fact that hypovitaminosis D is highly prevalent even in
the normal population [19], as also evidenced by the
mean 25OHVitD levels within the range of insufficiency
in our control group. Pooling data from our previous
and present extension study together consented us to
obtain the largest sample of PV and BP patients investi-
gated so far. Our data clearly demonstrated that vitamin
D levels are reduced in both PV and BP patients, sug-
gesting that hypovitaminosis D may have a pathogenetic
role in autoimmune bullous diseases. It is well-known
that PV and BP are autoantibody-driven autoimmune
disorders in which both T cells and B cells with auto-
reactivity towards DSG3 and BP180/BP230, respectively,
are necessary for their pathogenesis [10]. During acute
phase of PV and BP, auto-reactive T helper (Th)1 and
Th2 lymphocytes cooperatively play a role in the devel-
opment of the disease process [26]. Recently, a focus has
been placed on the contribution of the newly discovered
Th17 subset to the pathophysiology of both diseases,
since increased serum levels of the Th17-derived inter-
leukin (IL)-17, a pro-inflammatory cytokine contributing
to tissue damage, have been found in autoimmune blis-
tering diseases [17]. Finally, an impaired function of T
Figure 1 Correlation between vitamin D levels and ABSIS score. ABSIS score: bullous skin disorder intensity score (see reference #26). In the
whole group of patients the ABSIS score was inversely associated with 25OHVitD levels (R = −0.36, p < 0.005). All patients with 25OHVitD levels
above 15 ng/ml showed ABSIS score <20. On the other hand, in the presence of 25OHVitD levels below 15 ng/ml 22 and 28 patients showed
ABSIS score <20 and ≥20 respectively.
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tion is critical in preventing autoimmunity, has been ob-
served during the active phase of both diseases [17].
Thus, considering that vitamin D has modulatory effects
on B lymphocyte proliferation and immunoglobulin syn-
thesis [20; 27], its deficiency may increase autoantibody
production in autoimmune bullous diseases. Moreover,
vitamin D inhibits expression of Th1 cytokines, such as
IL-2, interferon-γ and tumor necrosis factor-α, thus
providing protection against autoimmunity [20]. In,
contrast, the effects of vitamin D on Th2 cells are con-
flicting, since it seems to inhibit Th2 cell differentiation,
but enhances the secretion of Th2-derived cytokines, like
IL-4 and IL-5 [20,16]. Finally, vitamin D can induce an in-
crease in T regs and a decrease in expression of IL-17 [20;
27], dampening autoimmune response and inflammation.
Thus, vitamin D supplementation may improve auto-
immune disorders associated with its deficiency like PV
and BP. Given the immune-modulatory properties of vita-
min D [13,14,20,27,28], our finding of the inverse correl-
ation between 25OHVitD levels and disease intensity, as
evaluated by the ABSIS score, further supports that the
low vitamin D levels, and most notably severe hypovita-
minosis D, may play a role in exacerbating the auto-
immune response in bullous diseases. In keeping, we
found that the disease intensity is invariably low in the
presence of 25OHVitD levels above 15 ng/ml, while it is
highly variable in the presence of severe hypovitamino-
sis D (Figure 1).
The possible association between the degree of the
autoimmune response and vitamin D is also suggestedby the presence in BP patients of an inverse correlation
between 25OHVitD and the BP180 serum levels. In PV
patients, the lack of a similar association between
25OHVitD levels and Dsg3-specific autoantibodies or
Dsg1-specific autoantibodies levels can be due to the
dramatically low 25OHVitD levels in most patients of
the study that may have hidden this relationship.
Beside these possible pathophysiological aspects, the
present study provides also some noteworthy clinical in-
formation. Indeed, previous studies reported that osteo-
porosis was more prevalent in PV patients as compared
with controls regardless of the use of glucocorticoids
[29] and that the glucocorticoid-induced BMD decrease
may be prevented by alendronate [30]. In the present
study, however, the finding of increased risk of fractures
in PV and BP patients regardless of BMD, suggests the
need of searching for morphometric VFx in these pa-
tients, even in the absence of clearly reduced BMD, as the
risk of fractures seems to be not entirely explained by a
decrease in bone density. It is possible to hypothesize that
in autoimmune bullous skin diseases a reduction of bone
quality contributes to the increased prevalence of frac-
tures, similarly to what happens in other forms of second-
ary osteoporosis [31]. In keeping, ALP and calcium levels
were found to be reduced in our both PV and BP patients,
likely indicating a low bone turnover and in particular im-
paired osteoblastic activity [32], which are known to be
important contributors for the maintenance of bone qual-
ity. From a clinical point of view, the awareness of a bone
involvement before the initiation of the commonly used
steroid therapy, may consent to prevent the occurrence of
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sent a medical emergency, and may worsen even further
the general health in patients affected with these rare but
potentially life-threatening skin diseases. As a conse-
quence, the prophylaxis of bone fractures in patients with
autoimmune bullous diseases should be considered even
in premenopausal women and men regardless of the use
of steroids.
Finally, the finding that the disease intensity is invariably
low in the presence of 25OHVitD levels above 15 ng/ml
(Figure 1) is completely novel. Although entirely specula-
tive, it is possible to hypothesize that 25OHVitD levels
within the normal range or at least above 15 ng/ml are
needed to reduce the risk of the recrudescence and/or re-
lapses of PV and BP. Further longitudinal and intervention
studies are needed to confirm this hypothesis.
In summary, as compared with the previous study
[15], the presents extension study provides some novel
important findings. Firstly, it demonstrates the presence
of an increased prevalence of VFx not only in BP but
also in PV patients separately analyzed. Secondly, the in-
creased number of patients included in the extension
study allowed to clarify that BMD is of limited useful-
ness in evaluating the propensity to VFx in patients with
autoimmune bullous skin diseases. Finally, the extension
study consented to reliably investigate the association be-
tween the 25OHVitD levels and disease intensity, suggest-
ing that the severely reduced vitamin D levels (particularly
below 15 ng/mL) may play a role in exacerbating the auto-
immune response in these patients.
The present study has some limits. Firstly, its cross-
sectional and observational design does not allow to look
for causality. Secondly, we did not assess the cytokine mi-
lieu and the most sensitive markers of bone apposition
and resorption that could have been more informative. Fi-
nally, the association between 25OHVitD levels with other
routinely used clinical scores, such as pemphigus disease
area index (PDAI) and bullous pemphigoid disease area
index (BPDAI) [24], has been not assessed. However, the
study has several strengths. Firstly, we could investigate a
relatively large sample of patients (considering the rarity
of these diseases) and obtain a quite comprehensive pic-
ture of the skeletal involvement in PV and BP. Secondly,
we studied only naïve patients and compared them with
strictly matched controls (who had the same setting of in-
patients). Finally, we took into account some potentially
confounding variables (i.e. smoking and sun exposure)
that might had influenced the results of previous studies.
Conclusions
The present study shows that PV and BP patients with
active disease have increased prevalence of severe hypo-
vitaminosis D, reduced 25OHVitD levels, inversely asso-
ciated with disease intensity, and increased prevalence ofvertebral fractures in spite of not reduced BMD. Of
interest, the association between the ABSIS score of cu-
taneous involvement and the vitamin D level, which has
never been previously reported by other investigators,
may have a direct implication in clinical practice. All the
above findings support the hypothesis of an influence of
vitamin D in triggering or exacerbating these auto-
immune disorders and suggest the need of evaluating
the skeletal health in PV and BP patients regardless of
steroid therapy. Further studies are needed to investigate
the possible causative role of hypovitaminosis D in PV
and BP and the possible therapeutic implications.
Additional file
Additional file 1: Table S1. Clinical characteristics of patients and
controls included in the extension study. Table S2. Clinical characteristics
of the whole sample of patients and controls.
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